Overview

Study of Iberdomide, Bortezomib, and Dexamethasone for ND-NTE MM Patients

Status:
Not yet recruiting
Trial end date:
2030-03-01
Target enrollment:
Participant gender:
Summary
This study will evaluate efficacy and tolerability of iberdomide, weekly bortezomib and dexamethasone administered in combination.
Phase:
Phase 2
Details
Lead Sponsor:
Canadian Myeloma Research Group
Treatments:
Bortezomib
Dexamethasone